ArticleCommunications medicine2025
Imaging and RNA sequencing-based radiogenomic analysis of occult lymph node metastasis and survival in lung adenocarcinoma staged non-metastatic.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of CT-based radiomics for predicting occult lymph node metastasis in early-stage lung adenocarcinoma: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Station 7 metastasis in upper lobe non-small cell lung cancer ≤2 cm: anatomical anomaly or marker of tumor aggressiveness?Journal of thoracic disease · 2026Article
- LANTERN-XGB: An Interpretable Multi-Modal Machine Learning for Improving Clinical Decision-Making in Lung Cancer.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to explore the value of a PET/CT-based radiomics signature in predicting occult lymph node metastasis (OLM) and outcomes in clinical N0 (cN0) lung adenocarcinoma (LUAD), to uncover the biologic meaning of OLM-associated radiomics phenotypes and to validate the reproducibility of the identified radiomics-correlated key genes.
methodsA radiomics signature for OLM prediction was developed in a training cohort and validated across multiple validation and testing cohorts in this multicenter study. Prognostic implications of the radiomics score (Radscore) were assessed by measuring recurrence-free survival. Biologic processes and pathways were enriched and correlated with Radscore and each of the 8 radiomics phenotypes using paired PET/CT and RNA sequencing data. The reproducibility of identified radiomics-associated key genes was validated using a public database, clinical tissue samples, and in vitro experiments.
resultsHere we show OLM is detected in 127 (19.9%) of 637 patients. The proposed signature achieves AUCs of 0.82, 0.81, 0.78 and 0.79 in the training, internal validation, prospective testing and external testing cohort, respectively. In addition, Radscore is identified as an independent predictive factor in predicting the risk of recurrence of LUAD. Furthermore, Radscore and OLM-related radiomics features are mostly associated with immune response. Finally, four key genes (MIR600HG, FAM13A-AS1, AQP4 and GRIA1), especially the MIR600HG gene, play important roles in OLM and prognosis of early-stage LUAD.
conclusionsWe demonstrate that radiogenomics performed on PET/CT images provides complementary clinical, prognostic and molecular information with great potential for the prediction of OLM and risk stratification in cN0 LUAD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.